Randall D. Marshall
Chief Tech/Sci/R&D Officer at Eumentis Therapeutics, Inc.
Randall D. Marshall active positions
| Companies | Position | Start | End |
|---|---|---|---|
Eumentis Therapeutics, Inc.
 Eumentis Therapeutics, Inc. Pharmaceuticals: GenericHealth Technology Eumentis Therapeutics, Inc. manufactures novel drugs. The American company was founded by Mark A. Tepper and he has been the CEO since incorporation. | Director/Board Member | - | - |
| Chief Tech/Sci/R&D Officer | - | - |
Career history of Randall D. Marshall
Former positions of Randall D. Marshall
| Companies | Position | Start | End |
|---|---|---|---|
Euthymics Bioscience, Inc.
 Euthymics Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Euthymics Bioscience, Inc. develops a novel medicine for alcohol use disorder (AUD) and smoking cessation. It engages in developing a medicine for central nervous system disorders of significant unmet medical need, including major depressive disorder (MDD) and alcohol use disorder (AUD). The firm provides Amitifadine, an antidepressant for major depressive disorder. The firm focuses on the modulation of neurotransmitters, including serotonin (5-HT), norepinephrine (NE), and dopamine (DA). The company was founded by Anthony A. McKinney and Franklin P. Bymaster in 2009 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 09/11/2011 | - |
Training of Randall D. Marshall
| The Johns Hopkins University | Doctorate Degree |
| Rice University | Undergraduate Degree |
Statistics
International
| United States | 5 |
Operational
| Corporate Officer/Principal | 1 |
| Doctorate Degree | 1 |
| Undergraduate Degree | 1 |
Sectoral
| Consumer Services | 3 |
| Commercial Services | 2 |
| Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 2 |
|---|---|
Euthymics Bioscience, Inc.
Euthymics Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Euthymics Bioscience, Inc. develops a novel medicine for alcohol use disorder (AUD) and smoking cessation. It engages in developing a medicine for central nervous system disorders of significant unmet medical need, including major depressive disorder (MDD) and alcohol use disorder (AUD). The firm provides Amitifadine, an antidepressant for major depressive disorder. The firm focuses on the modulation of neurotransmitters, including serotonin (5-HT), norepinephrine (NE), and dopamine (DA). The company was founded by Anthony A. McKinney and Franklin P. Bymaster in 2009 and is headquartered in Cambridge, MA. | Commercial Services |
Eumentis Therapeutics, Inc.
Eumentis Therapeutics, Inc. Pharmaceuticals: GenericHealth Technology Eumentis Therapeutics, Inc. manufactures novel drugs. The American company was founded by Mark A. Tepper and he has been the CEO since incorporation. | Health Technology |
- Stock Market
- Insiders
- Randall D. Marshall
- Experience
